CN1775222A - 一种治疗鼻腔疾病的盐水药液及应用装置 - Google Patents
一种治疗鼻腔疾病的盐水药液及应用装置 Download PDFInfo
- Publication number
- CN1775222A CN1775222A CN 200510100530 CN200510100530A CN1775222A CN 1775222 A CN1775222 A CN 1775222A CN 200510100530 CN200510100530 CN 200510100530 CN 200510100530 A CN200510100530 A CN 200510100530A CN 1775222 A CN1775222 A CN 1775222A
- Authority
- CN
- China
- Prior art keywords
- saline solution
- treatment
- nasal cavity
- chloride
- application device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 title claims abstract description 59
- 208000025938 nasal cavity disease Diseases 0.000 title 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 18
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 13
- 239000011780 sodium chloride Substances 0.000 claims abstract description 12
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000811 xylitol Substances 0.000 claims abstract description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 10
- 229960002675 xylitol Drugs 0.000 claims abstract description 10
- 235000010447 xylitol Nutrition 0.000 claims abstract description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 9
- 239000001110 calcium chloride Substances 0.000 claims abstract description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 9
- 239000001103 potassium chloride Substances 0.000 claims abstract description 9
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 208000030880 Nose disease Diseases 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 6
- 235000011148 calcium chloride Nutrition 0.000 claims description 3
- 229910001868 water Inorganic materials 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 13
- 206010039083 rhinitis Diseases 0.000 abstract description 3
- 230000002052 anaphylactic effect Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 239000012153 distilled water Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 18
- 206010039085 Rhinitis allergic Diseases 0.000 description 12
- 201000010105 allergic rhinitis Diseases 0.000 description 12
- 210000003928 nasal cavity Anatomy 0.000 description 11
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 9
- 238000000586 desensitisation Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 238000005507 spraying Methods 0.000 description 5
- 239000000739 antihistaminic agent Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 210000000492 nasalseptum Anatomy 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000158526 Nasalis Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 230000002612 cardiopulmonary effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 229940072265 rhinocort Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088529 claritin Drugs 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010006312 Breast swelling Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000002479 acid--base titration Methods 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种治疗鼻腔疾病的盐水药液及应用装置属药物和器械领域,尤适于对过敏性鼻炎的用药。本发明提出了治疗鼻腔疾病的新药物,其目的是提高疗效和无副作用;减少鼻炎症状复和病人所受的痛苦,降低治疗费用,配制和使用装置简单、方便。盐水药液由水、氯化钠、氯化钙、氯化钾和木糖醇组成;组份浓度重量百分比是:氯化钠0.002%-6%,氯化钙0.002%-1%,氯化钾0.002%-1%,木糖醇(1,2,3,4,5-戊五醇),)0.002%-0.2%。其余为蒸馏水。实践证明,长期应用盐水药液无副作用,价格便宜,患者乐于接受,应用喷雾方法的医疗效果更显著。
Description
技术领域:
本发明涉及一种治疗鼻腔疾病的盐水药液及应用装置,属药物和器械领域,尤适于对过敏性鼻炎的用药。
背景技术:
过敏性鼻炎是一种常见和多发的病,男女老少得了此病,会给工作、学习和生活带来不便,影响身心健康。此病很难根治,只能病发时吃药或用药滴鼻。过敏性鼻炎目前的治疗方法很多,主要有三种:
(1):抗组胺类药物,如:开瑞坦和信敏汀等。
(2):皮质激素类药物,如:雷诺考特鼻腔药等等。
(3):脱敏治疗:先找到相应的过敏原,再针对相应的过敏原进行皮下多次小剂量脱敏治疗。
过敏性鼻炎的脱敏治疗从理论上讲是一种非常有效的方法,但是实践证明,其真正的有效率也只在30%左右。
以上药物的治疗存在如下缺点:
一、抗组胺类药物和皮质激素类药物只能控制过敏性鼻炎的症状,很多病例在停药后过敏性鼻炎的症状立刻复发;
二、长期应用抗组胺药物和皮质激素会带来一定的副作用,如应用抗组胺类药物会引起头痛、嗜睡、疲乏、口干视觉模糊、血压降低或升高、心悸、晕厥、运动机能亢进、肝功能改变、黄疸、肝炎、肝坏死、脱发、癫痫发作、乳房肿大、多形性红斑及全身性过敏反应;应用皮质激素会可能引起鼻干、打喷嚏、轻微的血性分泌物或鼻出血、皮肤反应(荨麻疹、皮疹、皮炎、血管性水肿)极少数患者在鼻腔内给予糖皮质激素后有溃疡和鼻中隔穿孔。
三、脱敏疗法的时间长,费用高,每一脱敏疗程约4000圆,而且往往一个脱敏疗程不能奏效。脱敏治疗病人在治疗过程中所受的痛苦多,每周要到医院进行一次皮下注射脱敏抗原,至少持续半年以上。
发明内容:
本发明提供了治疗鼻腔疾病的新药物,其目的是提高疗效和对病人无副作用;减少鼻炎症状复发和病人所受的痛苦,降低治疗费用,配制和使用装置简单、方便。
一种治疗鼻腔疾病的盐水药液及应用装置,其特征在于盐水药液由水、氯化钠、氯化钙、氯化钾和木糖醇组成。
盐水药液组份浓度重量百分比是:氯化钠0.002%---6%,氯化钙0.002%---1%,氯化钾0.002%---1%,木糖醇(1,2,3,4,5-戊五醇),)0.002%--0.2%,其余为蒸溜水。
盐水药液酸碱度的PH值镞最好是7.0。
盐水药液对鼻腔有灌洗作用。空气中的过敏原在鼻腔粘膜聚居达到一定浓度时才能激发鼻腔粘膜产生过敏反应,从而出现相应的症状如:鼻痒、打喷嚏、流清涕、鼻塞等症状。此盐水药液中的水份能清理附着在鼻腔粘膜上的过敏原,从而避免过敏反应的发生。盐水药液中的氯化钠、氯化钙、氯化钾均为无机盐,能减轻鼻腔粘膜的水肿,同时这三种盐份在一起增加了药液的渗透压,高渗透压环境能抑制细菌的生长。木糖醇也有杀菌作用。
盐水药液的配制方法是:按组份浓度准备好蒸溜水和各组份,把蒸溜水放入经消毒的容器中,再把其余组份加进蒸溜水中,经搅拌使各组份完全溶解,即是盐水药液;此外,通过酸碱滴定的方发检测盐水药液的酸碱度,并添加微量个别组分控制盐水药液酸碱度的PH值为7.0左右。
应用盐水药液时,把盐水药液储盛在喷雾瓶内,用手轻轻按压,则瓶中的盐水通过喷头以雾状微粒的形式均匀分布在鼻腔内。这样,会达到最佳的灌洗作用和医疗效果。
上述盐水药液的氯化钠、氯化钙、氯化钾和木糖醇是药用品。
上述盐水药液的盐水药液经喷雾治疗过敏性鼻炎的疗效:经过临床观察,应用此盐水药液对鼻腔喷雾冲洗,每日3-5次,1月后,60%左右的过敏性鼻炎患者的症状得到控制;另外,若应用抗过敏药物和盐水药液治疗过敏性鼻炎,有40%左右患者的抗过敏药物的用量明显减少。盐水喷雾治疗的优点:在临床应用过程中确实有效,且长期应用无副作用,价格便宜,患者乐于接受。
具体实施方式:
现用几个例说明本方案。
例一
张××,男性,出生日期1956年7月12日。2001年5月因鼻痒、流清涕、打喷嚏伴轻度鼻塞而就诊。查体:一般情况好,心肺未见异常。外鼻无异常,双侧下鼻甲轻度肿大,鼻中隔无偏曲,鼻腔粘膜色白,鼻腔未见新生物。过敏原试验对粉尘、霉菌过敏。给予开瑞坦10mg,口服每日3次,1周后症状控制。以后过敏症状反复发作,每次应用开瑞坦控制症状。
2001年12份开始对鼻腔进行盐水药液喷雾治疗,每日3到5次,过敏性鼻炎症状再未复发。所花的费用仅50圆人民币
治疗本病例的盐水药液组份浓度配比是:每500ml盐水喷雾剂含有:氯化钠15克,氯化钙4克,氯化钾5克和0.5克的木糖醇(1,2,3,4,5-戊五醇),其余的是蒸溜水。盐水药液酸碱度的PH值为7.0
例二、
李××,男性,出生日期1970年9月19日。1999年6月因鼻痒、流清涕、打喷嚏就诊。查体:一般情况好,心肺未见异常。外鼻无异常,双侧下鼻甲无肿大,鼻中隔无偏曲,鼻腔粘膜色白,鼻腔未见新生物。过敏原试验对粉尘过敏。给予开瑞坦10mg口服每日3次,用雷诺考特,每日2次,3天后症状控制。以后过敏症状反复发作,每次应用开瑞坦和雷诺考特控制症状。
2002年5份开对鼻腔进行盐水药液喷雾治疗,每日3到5次,过敏性鼻炎症状至今再未复发,所花的费用仅60圆人民币
治疗本病例的盐水药液组份浓度配比是:每500ml盐水喷雾剂含有:氯化钠13克,氯化钙5克,氯化钾4克和0.6克木糖醇(1,2,3,4,5-戊五醇),其余的是蒸溜水。盐水药液酸碱度的PH值为7.0
例三、王××,女性,出生日期1978年10月12日。2003年7月因鼻痒、流清涕、打喷嚏伴耳鸣就诊。查体:一般情况好,心肺未见异常。外鼻无异常,双侧下鼻甲无肿大,鼻中隔无偏曲,鼻腔粘膜色白,鼻腔未见新生物。过敏原试验对粉尘过敏。给予开瑞坦10mg口服每日3次,3天后症状控制。以后过敏症状反复发作,每次应用开瑞坦控制症状。
2004年5份开始对鼻腔进行盐水药液喷雾治疗每日3到5次,过敏性鼻炎症状至今再未复发。所花的费用仅40圆人民币
治疗本病例的盐水药液组份浓度配比是:每500ml盐水喷雾剂含有:氯化钠170.4克的木糖醇(1,2,3,4,5-戊五醇),其余的是蒸溜水。盐水药液酸碱度的PH值为7.0
实践证明,盐水药液喷雾的医疗效果显著,经过治疗的鼻炎症状至今未再复发。
Claims (3)
1、一种治疗鼻腔疾病的盐水药液,其特征在于盐水药液由水、氯化钠、氯化钙、氯化钾和木糖醇组成;组份浓度重量百分比是:氯化钠0.002%---6%,氯化钙0.002%---1%,氯化钾0.002%---1%,木糖醇(1,2,3,4,5-戊五醇),)0.002%--0.2%。其余为蒸溜水。
2、根据权利要求1或2所述的一种治疗鼻腔疾病的盐水药液,其特征在于所述的盐水药液酸碱度的PH值为7.0。
4、根据权利要求1或2所述的一种治疗鼻腔疾病的盐水药液应用装置,其特征在于盐水药液应用装置是喷雾瓶。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101005304A CN100384435C (zh) | 2005-10-25 | 2005-10-25 | 一种治疗鼻腔疾病的盐水药液及应用装置 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101005304A CN100384435C (zh) | 2005-10-25 | 2005-10-25 | 一种治疗鼻腔疾病的盐水药液及应用装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1775222A true CN1775222A (zh) | 2006-05-24 |
CN100384435C CN100384435C (zh) | 2008-04-30 |
Family
ID=36765021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101005304A Active CN100384435C (zh) | 2005-10-25 | 2005-10-25 | 一种治疗鼻腔疾病的盐水药液及应用装置 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100384435C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109091497A (zh) * | 2018-10-16 | 2018-12-28 | 广州润虹医药科技股份有限公司 | 一种用于抗菌修复的清洗液及其制备方法 |
CN112739324A (zh) * | 2018-11-13 | 2021-04-30 | 赛义德·贾卢利 | 盐水组合物、其生产方法及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1325680A (zh) * | 2000-05-25 | 2001-12-12 | 穆英惠 | 鼻和鼻咽腔清洗液 |
CN1299770C (zh) * | 2004-05-31 | 2007-02-14 | 刘近周 | 多功能鼻腔和鼻窦洁疗液 |
-
2005
- 2005-10-25 CN CNB2005101005304A patent/CN100384435C/zh active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109091497A (zh) * | 2018-10-16 | 2018-12-28 | 广州润虹医药科技股份有限公司 | 一种用于抗菌修复的清洗液及其制备方法 |
CN112739324A (zh) * | 2018-11-13 | 2021-04-30 | 赛义德·贾卢利 | 盐水组合物、其生产方法及其用途 |
US11878032B2 (en) | 2018-11-13 | 2024-01-23 | Saïd DJELLOULI | Aqueous saline composition, process for the production of same, and use of same |
Also Published As
Publication number | Publication date |
---|---|
CN100384435C (zh) | 2008-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0648114B1 (de) | Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels | |
EP2099296B1 (en) | Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide | |
JP5693470B2 (ja) | 銀イオンおよびメントールを含む消毒剤組成物並びにその使用 | |
WO2000027390A1 (en) | Ionic silver complex | |
JP6656730B2 (ja) | 角膜創傷治癒および眼表面疾患のためのヒスタチン | |
US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
US20130259955A1 (en) | Medical Uses of Nanoclustered Water | |
CN102573831A (zh) | 用于治疗免疫相关病症的去铁胺-金属络合物 | |
KR101800851B1 (ko) | 국소 마취제 작용 시간 연장 진통제 | |
CN1775222A (zh) | 一种治疗鼻腔疾病的盐水药液及应用装置 | |
CN106511977A (zh) | 胶原贴敷料 | |
CN110269839A (zh) | 一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用 | |
CN109395068A (zh) | 一种难愈创口专用消毒液 | |
Serafini et al. | Recent patents on medicinal plants/natural products as a therapeutic approach to wounds and burns healing | |
AU2008335083A1 (en) | Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same | |
CN1989950A (zh) | 灭菌特效止痒搽剂 | |
CN1092046C (zh) | 用于愈合伤口的局部药物组合物 | |
CN106955291A (zh) | 一种抗菌消炎药剂及其制备方法 | |
US6805857B2 (en) | Method of modulating factor D, factor H and CD4 cell immune response with a polystyrene sulfonate, alginate, and saline infusion solution | |
WO2010119383A1 (en) | A medicinal cream made using framycetin sulphate cream and chitosan, and a process to make it | |
CN1306938C (zh) | 预防和治疗眼病的局部用药组合物 | |
Anyakudo et al. | Comparative Wound Healing Effects of Honey, Olive Oil, Pawpaw Fruit Extract and Iodine in Diabetic Rats: an Evaluation and Prioritization of Potential Alternative Therapeutic Options | |
RU2442592C1 (ru) | Фармацевтическая композиция "мицефосфон", стимулирующая регенерацию опорных тканей | |
CN1232263C (zh) | 含有稀土的治疗皮肤病的药物及其制备方法 | |
GB2624421A (en) | Scar tissue prophylaxis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161115 Address after: Huadu District, Guangdong city of Guangzhou province 510000 Flower Town Pingshan Private Industrial Park No. 16 south 5 Patentee after: GUANGZHOU YUNDUAN BAIYAN BIOTECHNOLOGY CO., LTD. Address before: Guangzhou City, Guangdong province 510100 Liuhua Road No. 111 building 109 Patentee before: Lu Yuhua |